High-Throughput Screening Identifies Novel Antileishmanial Scaffolds and Reveals Cross-Species Activity of Structurally Diverse Compounds

Leishmaniasis is a disease caused by microscopic parasites that live inside the cells of mammals, including humans. These parasites are carried by sand flies, and when the flies bite, they inject the parasites into the bloodstream. Once inside a person, the parasites hide within immune cells called macrophages, which normally fight off infection. Instead of being destroyed, the parasites turn these cells into safe houses where they multiply. This disease causes a wide range of suffering, from painful skin sores that can leave permanent scars to a severe form that attacks internal organs and can be fatal if left untreated. Currently, doctors have very few medicines to treat it, and the ones they do have often cause severe side effects, take a long time to work, or are becoming less effective as the parasites learn to resist them. Because the parasites hide so well inside human cells, finding new treatments is like looking for a needle in a haystack; a medicine must be strong enough to kill the parasite without harming the human cell it is hiding in.

To find new solutions, a team of researchers at the University of Notre Dame and Kean University turned to a method called high-throughput screening. Imagine a library containing thousands of different chemical compounds, each with a unique shape and structure. The researchers tested a vast collection of these chemicals to see which ones could stop the parasites from growing. They did not just look for any chemical that killed the parasite; they specifically looked for ones that could kill the parasite while leaving human cells unharmed. This process is crucial because a medicine that kills the parasite but also kills the patient is not a cure. The team focused on two specific groups of chemicals that appeared promising in earlier tests, along with a few unique, one-of-a-kind compounds that stood out from the rest.

The researchers tested these chemicals against the parasites at different stages of their life cycle. Some tests used the free-swimming form of the parasite, while others used the form that hides inside human cells, which is the stage that causes disease in people. They also checked how toxic the chemicals were to human cells grown in a lab. From this large group, they identified two main chemical structures that stood out as the most promising candidates. One structure, called a 1,4-diaryl-pyrazolo-pyridinone, and another called a pyrazolo-triazine, both showed the ability to kill the parasites effectively. The best version of the first structure killed the parasites hiding inside human cells at a very low concentration, while the best version of the second structure did the same, and both were safe for the human cells at those levels.

However, finding a chemical that works in a dish is only the first step. The researchers needed to know if these chemicals would behave well inside a living body. They ran a series of tests to see how the body might process these drugs, such as how quickly the liver would break them down or how well they would dissolve in water. The two leading chemicals behaved very differently. One dissolved easily in water but was broken down quickly by liver cells, suggesting it might need to be modified to stay in the body longer. The other was very stable and would likely stay in the body for a long time, but it did not dissolve as well in water, which could make it harder to deliver. These differences showed that while both were good starting points, they would need different kinds of improvements to become real medicines.

To see if these chemicals could be made even better, the researchers created dozens of new versions, or analogs, of the two leading structures. They made small changes to the shape of the molecules, like swapping out a single piece of the structure, to see how it affected their ability to kill the parasite. For the first structure, several of the new versions worked even better than the original, killing the parasites inside human cells more effectively while remaining safe for the cells. For the second structure, some new versions became incredibly powerful, killing the parasites at very low levels, though a few of these strong versions also became slightly more toxic to human cells. This process proved that both chemical structures could be fine-tuned to improve their performance.

The team also wanted to know if these chemicals would work against different types of the parasite that cause the disease in different parts of the world. They tested the leading chemicals against three different species of the parasite. The results showed that while the chemicals worked against all three, they were not equally strong against each one. Some worked very well against one species but were weaker against another. This finding is important because it suggests that a drug developed for one type of parasite might not work perfectly for another, and researchers must test their candidates against the specific types of parasites found in different regions. They also tested the chemicals against a different parasite that causes a related disease, but found that the chemicals were much less effective against it, indicating that these new drugs are likely specific to the parasites that cause leishmaniasis.

The study concluded that these two chemical structures are excellent starting points for developing new medicines. The researchers did not claim to have found a cure, but rather a solid foundation to build upon. They showed that by carefully testing how these chemicals behave in different conditions and by making small, precise changes to their structure, it is possible to create compounds that are both powerful against the parasite and safe for the patient. The work highlights the importance of testing drugs against the specific form of the parasite that lives inside human cells and against the different species that cause the disease around the world. By following this careful path of testing and refining, the researchers have provided a clear direction for future work that could eventually lead to safer and more effective treatments for millions of people suffering from this neglected disease.